The Centers for Medicare & Medicaid Services has selected 61 applicants for the Value in Opioid Use Disorder Treatment Demonstration, a four-year Medicare payment model beginning this month for selected health care providers who agree to participate.

Participants will test whether a new care management fee and performance-based incentive payment for OUD treatment services reduces hospitalizations and improves health outcomes for Medicare fee-for-service patients with OUDs, including those dually eligible for Medicaid. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 authorizes $10 million annually in fiscal years 2021-2024 to pay for the treatment services. 

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The House Ways and Means Committee today advanced its portion of the fiscal year 2025 reconciliation bill by a 26-19 vote along party lines, following an hours…